185 related articles for article (PubMed ID: 32770960)
1. The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models.
Ramelow J; Brooks CD; Gao L; Almiman AA; Williams TM; Villalona-Calero MA; Duan W
BMC Cancer; 2020 Aug; 20(1):738. PubMed ID: 32770960
[TBL] [Abstract][Full Text] [Related]
2. Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice.
Duan W; Gao L; Kalvala A; Aguila B; Brooks C; Mo X; Ding H; Shilo K; Otterson GA; Villalona-Calero MA
Int J Cancer; 2019 Nov; 145(9):2418-2426. PubMed ID: 30873587
[TBL] [Abstract][Full Text] [Related]
3. Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice.
Duan W; Ding H; Subler MA; Zhu WG; Zhang H; Stoner GD; Windle JJ; Otterson GA; Villalona-Calero MA
Oncogene; 2002 Nov; 21(51):7831-8. PubMed ID: 12420220
[TBL] [Abstract][Full Text] [Related]
4. Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice.
Duan W; Gao L; Wu X; Hade EM; Gao JX; Ding H; Barsky SH; Otterson GA; Villalona-Calero MA
PLoS One; 2009; 4(5):e5563. PubMed ID: 19440353
[TBL] [Abstract][Full Text] [Related]
5. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
Wang Y; Zhang Z; Kastens E; Lubet RA; You M
Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
[TBL] [Abstract][Full Text] [Related]
6. Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke.
De Flora S; Balansky RM; D'Agostini F; Izzotti A; Camoirano A; Bennicelli C; Zhang Z; Wang Y; Lubet RA; You M
Cancer Res; 2003 Feb; 63(4):793-800. PubMed ID: 12591728
[TBL] [Abstract][Full Text] [Related]
7. Use of p53 transgenic mice in the development of cancer models for multiple purposes.
Lubet RA; Zhang Z; Wiseman RW; You M
Exp Lung Res; 2000 Dec; 26(8):581-93. PubMed ID: 11195457
[TBL] [Abstract][Full Text] [Related]
8. Similar incidence of K-ras mutations in lung carcinomas of FVB/N mice and FVB/N mice carrying a mutant p53 transgene.
Shafarenko M; Mahler J; Cochran C; Kisielewski A; Golding E; Wiseman R; Goodrow T
Carcinogenesis; 1997 Jul; 18(7):1423-6. PubMed ID: 9230291
[TBL] [Abstract][Full Text] [Related]
9. A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin.
Zhang Z; Liu Q; Lantry LE; Wang Y; Kelloff GJ; Anderson MW; Wiseman RW; Lubet RA; You M
Cancer Res; 2000 Feb; 60(4):901-7. PubMed ID: 10706103
[TBL] [Abstract][Full Text] [Related]
10. Lung-specific expression in mice of a dominant negative mutant form of the p53 tumor suppressor protein.
Morris GF; Hoyle GW; Athas GB; Lei WH; Xu J; Morris CB; Friedman M
J La State Med Soc; 1998 Apr; 150(4):179-85. PubMed ID: 9610073
[TBL] [Abstract][Full Text] [Related]
11. Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf.
Zhang Z; Wang Y; Lantry LE; Kastens E; Liu G; Hamilton AD; Sebti SM; Lubet RA; You M
Oncogene; 2003 Sep; 22(40):6257-65. PubMed ID: 13679864
[TBL] [Abstract][Full Text] [Related]
12. Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice.
Duan W; Gao L; Jin D; Otterson GA; Villalona-Calero MA
Transgenic Res; 2008 Jun; 17(3):355-66. PubMed ID: 17968669
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of JSRV envelope transgenic mice in FVB background.
Chitra E; Yu SL; Hsiao KN; Shao HY; Sia C; Chen IH; Hsieh SY; Chen JH; Chow YH
Virology; 2009 Oct; 393(1):120-6. PubMed ID: 19695657
[TBL] [Abstract][Full Text] [Related]
14. Lung-specific expression of dominant-negative mutant p53 in transgenic mice increases spontaneous and benzo(a)pyrene-induced lung cancer.
Tchou-Wong KM; Jiang Y; Yee H; LaRosa J; Lee TC; Pellicer A; Jagirdar J; Gordon T; Goldberg JD; Rom WN
Am J Respir Cell Mol Biol; 2002 Aug; 27(2):186-93. PubMed ID: 12151310
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
[TBL] [Abstract][Full Text] [Related]
16. Lung-Enriched Mutations in the p53 Tumor Suppressor: A Paradigm for Tissue-Specific Gain of Oncogenic Function.
Barta JA; McMahon SB
Mol Cancer Res; 2019 Jan; 17(1):3-9. PubMed ID: 30224539
[TBL] [Abstract][Full Text] [Related]
17. Gene expression in the lung of p53 mutant mice exposed to cigarette smoke.
Izzotti A; Cartiglia C; Longobardi M; Bagnasco M; Merello A; You M; Lubet RA; De Flora S
Cancer Res; 2004 Dec; 64(23):8566-72. PubMed ID: 15574763
[TBL] [Abstract][Full Text] [Related]
18. The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity.
Kawamura M; Yamashita T; Segawa K; Kaneuchi M; Shindoh M; Fujinaga K
Oncogene; 1996 Jun; 12(11):2361-7. PubMed ID: 8649776
[TBL] [Abstract][Full Text] [Related]
19. p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells.
Dong P; Tada M; Hamada J; Nakamura A; Moriuchi T; Sakuragi N
Clin Exp Metastasis; 2007; 24(6):471-83. PubMed ID: 17636407
[TBL] [Abstract][Full Text] [Related]
20. K-ras mutations in lung tumors from A/J and A/J x TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate.
Matzinger SA; Crist KA; Stoner GD; Anderson MW; Pereira MA; Steele VE; Kelloff GJ; Lubet RA; You M
Carcinogenesis; 1995 Oct; 16(10):2487-92. PubMed ID: 7586156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
